BDB-201 is under clinical development by Seven and Eight Biopharmaceuticals and currently in Phase I for Metastatic Liver Cancer. According to GlobalData, Phase I drugs for Metastatic Liver Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the BDB-201 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BDB-201 overview

Orien X-010 (BDB-201) is under development for the treatment of acral melanoma, metastatic liver cancer and solid tumors. The drug candidate is administered through intratumor route. The drug candidate consists of a replicating recombinant attenuated herpes simplex virus type I (Type I Herpes Simplex Virus, HSV-1) oncolytic vectors isolated from Chinese Han population. The genotype of HSV-1 was deleted from the genome of OrienX-010 and the DNA fragment encoding human GM-CSF was inserted so that the product only replicates specifically in tumor cells.

Orien X-010 was also under development for the treatment of malignant solid tumors including liver cancer, pancreatic cancer and lung cancer.

Seven and Eight Biopharmaceuticals overview

Seven and Eight Biopharmaceuticals is mainly engaged in the business of providing immunotherapies for cancer treatment using dendritic cell reprogramming and agonists. The company is headquartered in New Brunswick, New Jersey, the US.

For a complete picture of BDB-201’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.